Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab

References

• NorisMRemuzziGAtypical hemolytic-uremic syndromeN Engl J Med2009361171676168719846853
   PubMed Web of Science ®Google Scholar
• ZipfelPFHeinenSSkerkaCThrombotic microangiopathies: new insights and new challengesCurr Opin Nephrol Hypertens201019437237820539230
   PubMed Web of Science ®Google Scholar
• BenzKAmannKThrombotic microangiopathy: new insightsCurr Opin Nephrol Hypertens201019324224720186056
   PubMed Web of Science ®Google Scholar
• NorisMCaprioliJBresinERelative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotypeClin J Am Soc Nephrol20105101844185920595690
   PubMed Web of Science ®Google Scholar
• CampistolJMAriasMAricetaGAn update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. [Actualización en síndrome hemolitico urémico atipico: diagnóstico y tratamiento. Documento de consenso]Nefrologia20133312745 English and Spanish23364625
   PubMed Web of Science ®Google Scholar
• CatónBDíaz de OtazuRAldamiz-EchebarriaMViguriAHaemolytic-uraemic syndrome with thrombotic microangiopathy of the retina following cytomegalovirus infection: postmortem findingsPostgrad Med J1993698146536558234116
   PubMed Web of Science ®Google Scholar
• BenzimraREAntaoAJDonovanKLWilliamsAJThe association between retinal ischaemia and end-stage renal damage in thrombotic microangiopathyQJM19989164174229709460
   PubMed Web of Science ®Google Scholar
• LarakebALeroySFrémeaux-BacchiVOcular involvement in hemolytic uremic syndrome due to factor H deficiency – are there therapeutic consequences?Pediatr Nephrol200722111967197017619907
   PubMed Web of Science ®Google Scholar
• DavidRHochberg-KleinSAmerRResolution of ocular involvement with systemic eculizumab therapy in atypical hemolytic-uremic syndromeEye (Lond)201327899799823722719
   PubMed Web of Science ®Google Scholar
• ZhengXGorovoyIRMaoJJinJChenXCuiQNRecurrent ocular involvement in pediatric atypical hemolytic uremic syndromeJ Pediatr Ophthalmol Strabismus201451e62e65
   Web of Science ®Google Scholar
• Alexion Pharmaceuticals IncSoliris^® (eculizumab) [prescribing information]Cheshire, CTAlexion Pharmaceuticals, Inc2014 Available from: http://www.soliris.net/sites/default/files/assets/soliris_pi.pdfAccessed September 8, 2015
   Google Scholar
• Alexion Europe SASSoliris (eculizumab) [summary of product characteristics]European Medicines Agency2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000791/WC500054210.pdfAccessed September 8, 2015
   Google Scholar
• LegendreCMLichtCMuusPTerminal complement inhibitor eculizumab in atypical hemolytic-uremic syndromeN Engl J Med2013368232169218123738544
   PubMed Web of Science ®Google Scholar
• LichtCGreenbaumLAMuusPEfficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studiesKidney Int20158751061107325651368
   PubMed Web of Science ®Google Scholar
• GreenbaumLAFilaMTsimaratosMEculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in pediatric atypical hemolytic uremic syndrome (aHUS) patients (Pts)J Am Soc Nephrol201324821A822A
   Google Scholar
• FakhouriFHourmantMCampistolJMEculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in adult atypical hemolytic uremic syndrome (aHUS) patients (Pts)J Am Soc Nephrol20132449A50A
   Google Scholar
• ZuberJFakhouriFRoumeninaLTLoiratCFrémeaux-BacchiVFrench Study Group for aHUS/C3GUse of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathiesNat Rev Nephrol201281164365723026949
   PubMed Web of Science ®Google Scholar
• CoppoPSchwarzingerMBuffetMFrench Reference Center for Thrombotic MicroangiopathiesPredictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA Reference Center experiencePLoS One201054e1020820436664
   PubMed Web of Science ®Google Scholar
• CatalandSRWuHMHow I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndromeBlood2014123162478248424599547
   PubMed Web of Science ®Google Scholar
• HagemanGSAndersonDHJohnsonLVA common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degenerationProc Natl Acad Sci U S A2005102207227723215870199
   PubMed Web of Science ®Google Scholar
• ThakkinstianAHanPMcEvoyMSystematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degenerationHum Mol Genet200615182784279016905558
   PubMed Web of Science ®Google Scholar
• HerbertAPDeakinJASchmidtCQStructure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphismJ Biol Chem200728226189601896817360715
   PubMed Web of Science ®Google Scholar
• HoferJRosalesAFischerCGinerTExtra-renal manifestations of complement-mediated thrombotic microangiopathiesFront Pediatr201429725250305
   PubMed Web of Science ®Google Scholar
• NeuhausTJCalonderSLeumannEPHeterogeneity of atypical haemolytic uraemic syndromesArch Dis Child19977665185219245850
   PubMed Web of Science ®Google Scholar
• Sellier-LeclercALFremeaux-BacchiVDragon-DureyMAFrench Society of Pediatric NephrologyDifferential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndromeJ Am Soc Nephrol20071882392240017599974
   PubMed Web of Science ®Google Scholar
• GeerdinkLMWestraDvan WijkJAAtypical hemolytic uremic syndrome in children: complement mutations and clinical characteristicsPediatr Nephrol20122781283129122410797
   PubMed Web of Science ®Google Scholar
• Dragon-DureyMASethiSKBaggaAClinical features of anti-factor H autoantibody-associated hemolytic uremic syndromeJ Am Soc Nephrol201021122180218721051740
   PubMed Web of Science ®Google Scholar
• OhanianMCableCHalkaKEculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndromeClin Pharmacol2011351222287852
   PubMedGoogle Scholar
• BekassyZDKristofferssonACCronqvistMEculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesionsNephrol Dial Transplant201328112899290724009284
   PubMed Web of Science ®Google Scholar
• Román-OrtizEMendizabal OteizaSPintoSLópez-TrascasaMSánchez-CorralPRodríguez de CordobaSEculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid genePediatr Nephrol201429114915323982707
   PubMed Web of Science ®Google Scholar
• ÁvilaAVizcaínoBMolinaPGavelaEPerez-EbriMPallardóLRemission of aHUS neurological damage with eculizumabClin Kidney J20158223223625815183
   PubMedGoogle Scholar
• GullerogluKFidanKHançerVSBayrakciUBaskinESoylemezogluONeurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumabPediatr Nephrol201328582783023389237
   PubMed Web of Science ®Google Scholar
• PoveyHVundruRJungleeNJibaniMRenal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysisClin Nephrol201482532633123557793
   PubMed Web of Science ®Google Scholar
• Diamante ChiodiniBDavinJCCorazzaFEculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndromePediatrics20141336e1764e176824843055
   PubMed Web of Science ®Google Scholar
• HuHNagraAHaqMRGilbertRDEculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvementPediatr Nephrol20142961103110624317637
   PubMed Web of Science ®Google Scholar
• TsaiHMKuoEEculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndromeAdv Hematol2014201429532325400666
   PubMedGoogle Scholar
• VilaltaRLaraEMadridALong-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndromePediatr Nephrol201227122323232622890512
   PubMed Web of Science ®Google Scholar
• MalinaMGulatiABaggaAMajidMASimkovaESchaeferFPeripheral gangrene in children with atypical hemolytic uremic syndromePediatrics20131311e331e33523230076
   PubMed Web of Science ®Google Scholar
• GreenHHarariEDavidovitsMAtypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumabRen Fail20143671119112124828571
   PubMed Web of Science ®Google Scholar
• WebbTHGriffithsHMiyashitaYAtypical hemolytic uremic syndrome and chronic ulcerative colitis treated with eculizumabInt J Med Pharm Case Reports201545105112
   Google Scholar
• ArdissinoGTelFTestaSSkin involvement in atypical hemolytic uremic syndromeAm J Kidney Dis201463465265524290245
   PubMed Web of Science ®Google Scholar